Articles and Links

Curated resources about preserving kidney function and advancements in kidney care.

Funancial News

People with chronic kidney disease can now monitor their kidney health at home using a test kit and a smartphone.


IgA nephropathy (IgAN) is the most common cause of primary (idiopathic) glomerulonephritis in resource-abundant settings.
The treatment and prognosis of IgAN will be reviewed here.

Healio News

Patients with advanced chronic kidney disease who choose not to use dialysis can survive many years with improvements to their mental health, in addition to stable physical health and quality of life until late into the illness, data show.

Healio News

A newly release Morbidity and Mortality Weekly Report shows a 41.8% increase in incident end-stage kidney disease cases and a 118.7% increase in prevalent cases across the United States between 2000 and 2019.

Healio News

The EMPA-Kidney trial will stop early due to evidence of Jadiance’s positive efficacy among patients with chronic kidney disease…

Healio News

Diabetic kidney disease is the leading cause of end-stage renal disease in the U.S., and 50% of adults initiating renal replacement therapy have diabetes…Until recently, there were no proven therapies that could substantially alter the timeline to ESRD or CV death for this population. Now, new agents are upending the treatment paradigm for DKD, offering the promise of delaying or even preventing dialysis, along with significant reduction in heart failure hospitalization risk and CV death.

Institute for Healthcare Improvement

A nephrologist in rural Texas heard about an innovative model of care in Sweden at the IHI National Forum. Five years later, his patients are doing their own dialysis — with half the rate of hospitalizations.

Healio News

We are encouraged to see the need for change in kidney care recognized in this article. Pandemics expose critical weaknesses in our health care system and doctors need to get out ahead of the problem.

NEJM Catalyst

Dr. Gibney shared an encouraging conversation with Barry Smith, M.D., a nephrologist with Rogosin Institute covering New York Presbyterian Hospital. Despite serving at a critical epicenter of the COVID-19 pandemic, their organization is dramatically innovating to improve outcomes and experience.

Healio News

A great read on social determinants of health, story-sharing, and patient advocacy. Thank you to Rita K. Kuwahara, MD, MIH!

Healio News

“Our traditional training and practice of nephrology focus on the disease and are guided by population-based patterns. This approach, however, does not consider the unique physical, emotional and social characteristics of the person with the disease, or their values and aspirations.”

Healio News

“The USRDS has already shown that 92% of CKD 1-3 patients are UNAWARE that they have kidney disease. Recently a different study by the National Kidney Foundation found that 80% of patients with diabetes and/or hypertension do not receive appropriate testing for CKD. This is a huge problem if we can’t identify and communicate with the people who are most at-risk.” – Dr. Richard Gibney


Do SGLT-2 inhibitors really help preserve kidney function for patients with CKD? The American Society of Nephrology says YES… “It is imperative for clinicians to assess the use of SGLT2is in medically eligible patients and prescribe these agents when appropriate.”

HCP Live

New risk assessment tools incorporating glomerular filtration rate (GFR) and albuminuria can help manage treatment for chronic kidney disease (CKD).

The New England Journal of Medicine

Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.

Healio News

For Silvio E. Inzucchi, MD, a simple question from a patient who underwent coronary artery bypass graft surgery would spur an interest in clinical research that helped lead to paradigm-changing discoveries.

Healio News

In April, the FDA approved use of dapagliflozin (Farxiga, AstraZeneca) to reduce the risk for kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.


One the biggest problems with many of today’s treatment options for people with type 2 diabetes is that while they help lower blood sugar levels they can actually lead to weight gain. That’s why the early results from two clinical trials of this new drug for type 2 diabetes is significantly exciting.

Frontiers in Pharmacology

Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide. Mineralocorticoid receptor (MR) plays an important role in the development of DKD. A series of preclinical studies revealed that MR is overactivated under diabetic conditions, resulting in promoting inflammatory and fibrotic process in the kidney.

Healio News

In this video, George L. Bakris, MD, a professor of medicine and the director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about FIDELITY data released at ASN Kidney Week.

Healio News

George L. Bakris, MD, a professor of medicine and the director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about a new subgroup analysis of the FIGARO-DKD trial.

Healio News

The FDA granted breakthrough therapy designation to the SGLT2 inhibitor dapagliflozin for adults with chronic kidney disease with and without type 2 diabetes, according to an industry press release.

Healio News

There was no significant difference in results when giving finerenone with or without sodium-glucose cotransporter-2 inhibitors to patients with type 2 diabetes and chronic kidney disease, according to a speaker at ASN Kidney Week.

Healio News

The initiation of SGLT-2 inhibitors correlated with a reduced risk of AKI in older adults with type 2 diabetes compared with other glucose-lowering medications. According to data published in the American Journal of Kidney Diseases, SGLT-2 inhibitors (SGLT-2i) may prevent AKI events.

New DAPA-CKD trial analyses have confirmed the outstanding renoprotective benefits of sodium–glucose co-transporter 2 inhibitors, independently of the presence of diabetes or the stage of kidney disease.

Diabetic kidney disease is the leading cause of kidney failure worldwide; in the USA, it accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike other complications of diabetes, the prevalence of diabetic kidney disease has failed to decline over the past 30 years….Sodium–glucose co-transporter 2 (SGLT2) inhibitors have a beneficial impact on many of these pathophysiological abnormalities

There are few data on the absolute effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors, despite their importance in treatment decision making. We investigated absolute treatment effects according to baseline kidney disease status.


A new treatment option, FARXIGA® (dapagliflozin), has been proven to help slow the progression of CKD – a huge scientific innovation for CKD patients at risk of progression with and without T2D. This approval is the most significant advancement in the treatment of CKD in over 20 years.

American Society of Nephrology (ASN): Kidney360

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have emerged as an effective therapy for improving outcomes in diabetic and nondiabetic kidney disease. Clinical trials have demonstrated the benefits of SGLT2is for secondary prevention of adverse cardiovascular (CV) effects in patients with established atherosclerotic disease and/or heart failure with reduced ejection fraction. It is imperative for clinicians to assess the use of SGLT2is in medically eligible patients and prescribe these agents when appropriate.

American Journal of Kidney Diseases (AJKD)

To clarify and support the role of SGLT2 inhibitors for treatment of type two diabetes, cardiocastulcar disease, and kidney disease, the National Kidney Foundation convened a scientific workshop with an international panel of more than 80 experts.

Resources delivered to your inbox

Sign up below to receive more stories, encouragement, and educational resources delivered straight to your email inbox.